Sleep Medicine · Supplementary · from Sleep Medicine

Case 2: Narcolepsy Type 1

Patient Presentation

Demographics: 19-year-old male college freshman, pre-engineering major

Chief Complaint: "I keep falling asleep in class no matter how much sleep I get, and sometimes my legs buckle when I laugh really hard."

History of Present Illness: The patient is a college freshman who presents to the student health sleep clinic with a 3-year history of excessive daytime sleepiness that has significantly worsened since starting college. He reports irresistible sleep attacks occurring 3-5 times daily, lasting 10-20 minutes, after which he briefly feels refreshed. These episodes occur in class, during meals, in conversations, and even while standing. He reports sleeping 8-9 hours per night and yet wakes feeling unrefreshed.

His most concerning symptom, which he describes with embarrassment, is sudden episodes of bilateral knee buckling and jaw dropping that occur exclusively during strong positive emotions — typically when laughing hard with friends, hearing a good joke, or feeling surprised. These episodes last 5-30 seconds, during which he is fully conscious but unable to move or speak. He has fallen to the ground completely three times in the past year. He does not lose consciousness during these episodes. His roommate initially thought he was "faking it" or "goofing around."

He also reports vivid, often frightening hallucinations as he is falling asleep (hypnagogic), including seeing shadowy figures in his room, hearing his name called, and feeling a presence on his chest. On several occasions, he has awakened from sleep completely unable to move for 1-2 minutes despite being fully aware of his surroundings (sleep paralysis), which he finds terrifying. He also reports disrupted nighttime sleep with frequent awakenings (3-4 times per night) and vivid dreams.

His symptoms began around age 16, initially with excessive sleepiness that was attributed to typical teenage sleep patterns, growth, and academic stress. The cataplexy episodes began approximately 6 months later but were initially mild (facial muscle twitching when laughing) and were not recognized. He reports that his symptoms led to significant academic decline in high school and social withdrawal. He was evaluated by his pediatrician at age 17, who diagnosed "possible depression" and started sertraline, which provided no improvement in sleepiness.

Past Medical History:

• No significant medical history
• Influenza-like illness at age 15 with prolonged fatigue (in retrospect, possible onset trigger)
• No history of head trauma
• H1N1 influenza vaccination at age 9 (Pandemrix — the adjuvanted H1N1 vaccine associated with narcolepsy in epidemiological studies was NOT used in the US; he received the standard US-approved vaccine)
• Depression diagnosis at age 17 (likely secondary to undiagnosed narcolepsy)
• No allergies

Medications:

• Sertraline 50 mg daily (started at age 17 for "depression")
• No stimulant medications previously prescribed
• Energy drinks: 2-3 per day (reports minimal benefit)

Social History:

• College freshman, pre-engineering major; academic probation due to falling asleep in class and missing assignments
• Lives in a dorm with a roommate
• Denies alcohol, tobacco, or recreational drug use
• Single; reports social isolation due to embarrassment about cataplexy episodes
• Sleeps 8-9 hours at night with frequent awakenings; naps 2-3 times daily
• No shift work
• Does not drive (was afraid to get his license because of sleepiness)

Family History:

• No family history of narcolepsy or excessive sleepiness
• Mother: migraine
• Father: healthy
• Siblings: one younger sister, healthy

Physical Examination

• Vital Signs: BP 118/74 mmHg, HR 72 bpm, RR 14/min, Temp 36.8°C, Weight 82 kg, Height 178 cm, BMI 25.9 kg/m²
• General: Well-appearing young male; falls asleep during the examination on two occasions (brief, easily arousable); slightly overweight
• Epworth Sleepiness Scale (ESS): Score 20/24 (severe excessive sleepiness)
• Stanford Sleepiness Scale: 5/7 at time of visit ("foggy; losing interest in remaining awake")
• HEENT: Normal oropharynx; Mallampati class II; no tonsillar hypertrophy; nasal airway patent
• Neurological: Cranial nerves II-XII intact; motor strength 5/5 in all extremities (no weakness between cataplexy episodes); deep tendon reflexes 2+ and symmetric; coordination normal; no ataxia; gait normal
• During the examination: One brief episode of jaw dropping and head nodding when the patient laughed at a joke — lasted approximately 10 seconds with full awareness maintained; witnessed cataplexy
• Mental status: Alert (when awake); oriented x 3; affect is flat (likely related to chronic sleepiness and social withdrawal); PHQ-9 score: 12 (moderate depression)

Workup and Results

Laboratory Studies:

Imaging/Additional Studies:

• Overnight polysomnography (PSG):
• Total sleep time: 408 minutes; Sleep efficiency: 89%
• Sleep latency: 3 minutes (markedly shortened)
• REM latency: 8 minutes (sleep-onset REM period — SOREMP)
• Sleep architecture: Increased N1 (22%); fragmented sleep with 38 arousals; two SOREMPs during the nocturnal recording
• AHI: 2.1 events/hour (no significant sleep apnea — rules out OSA as cause of sleepiness)
• PLMI: 3/hour (not significant)
• No evidence of nocturnal seizures on EEG

• Multiple Sleep Latency Test (MSLT) — performed the day following PSG (sertraline held for 2 weeks prior per protocol):
• 5 nap opportunities at 2-hour intervals (09:00, 11:00, 13:00, 15:00, 17:00)
• Mean sleep latency: 2.4 minutes (normal >8 minutes; pathological sleepiness <8 minutes; <5 minutes consistent with severe hypersomnolence)
• SOREMPs: 4 out of 5 naps (REM sleep within 15 minutes of sleep onset)
• MSLT diagnostic criteria for narcolepsy met: mean sleep latency <=8 minutes AND >=2 SOREMPs (including any SOREMP on the preceding PSG)

• Brain MRI: Normal; no hypothalamic lesions, no masses, no structural abnormalities

Clinical Image

Educational diagram illustrating the pathophysiology of narcolepsy type 1, showing autoimmune destruction of hypocretin (orexin)-producing neurons in the lateral hypothalamus, and the resulting disruption of sleep-wake regulation. Source: Educational illustration.

Diagnosis

Narcolepsy Type 1 (Narcolepsy with Cataplexy)

Key Diagnostic Criteria (ICSD-3):

• Excessive daytime sleepiness daily for >=3 months (present for 3 years)
• Definite cataplexy: episodes of sudden, bilateral loss of muscle tone precipitated by strong emotions (laughter, surprise) with preserved consciousness — pathognomonic for narcolepsy type 1
• MSLT: mean sleep latency 2.4 minutes (<=8 minutes) with 4 SOREMPs (>=2 required)
• CSF hypocretin-1: 18 pg/mL (<110 pg/mL) — confirmatory and considered the gold standard diagnostic test for NT1; reflects >90% loss of hypothalamic hypocretin-producing neurons
• HLA-DQB1*06:02 positive — supports autoimmune etiology (present in >98% of NT1 patients)
• The classic "narcolepsy tetrad": (1) excessive daytime sleepiness (present), (2) cataplexy (present), (3) hypnagogic hallucinations (present), (4) sleep paralysis (present) — all four present in this patient (complete tetrad occurs in only ~10-15% of patients)

Treatment Plan

1. Pharmacotherapy for excessive daytime sleepiness:

• First-line: Modafinil 200 mg in the morning, may increase to 200 mg BID (morning and noon) if needed; OR
• Alternative first-line: Solriamfetol 75 mg daily, titrate up to 150 mg (dual-action dopamine/norepinephrine reuptake inhibitor; recently approved and effective)
• If insufficient response: Add sodium oxybate (Xyrem) 4.5 g at bedtime in two divided doses (taken at bedtime and 2.5-4 hours later); consolidates nighttime sleep, reduces cataplexy and daytime sleepiness — the only medication that addresses all narcolepsy symptoms
• Alternative: Low-sodium oxybate (Xywav) — preferred formulation due to lower sodium content
• Second-line stimulants if needed: Methylphenidate or dextroamphetamine (avoid if possible in a college setting due to abuse potential and scheduling concerns)

1. Pharmacotherapy for cataplexy:

• Continue sertraline (or switch to venlafaxine 75-150 mg) — SSRIs/SNRIs suppress REM sleep and reduce cataplexy frequency by 50-80%
• Sodium oxybate is the most effective anti-cataplexy agent and may replace antidepressant therapy
• Pitolisant (histamine H3 receptor inverse agonist): 17.8-35.6 mg daily — non-scheduled, effective for both sleepiness and cataplexy

1. Behavioral sleep management:

• Scheduled naps: Two 15-20 minute naps daily (between classes — e.g., 11:00 and 15:00) — brief naps are refreshing in narcolepsy and reduce sleep attack frequency
• Regular sleep schedule: consistent bedtime and wake time (including weekends); avoid sleep deprivation (worsens all symptoms)
• Avoid alcohol and heavy meals (worsen sleepiness and cataplexy)
• Eliminate caffeine after noon; reduce energy drink consumption
• Strategic timing of important activities during peak alertness

1. Academic accommodations (coordinate with disability services):

• Document narcolepsy as a disability under ADA and Section 504
• Accommodations: extended testing time, permission to record lectures, flexible attendance policy, permission for scheduled naps, preferential seating (front row), reduced course load if needed
• Academic advisor notification with student's permission

1. Safety and driving:

• Driving evaluation after sleepiness is adequately treated and stable for >=3 months
• Document treatment response and physician clearance before driving
• Avoid driving during known vulnerable times (early afternoon, after meals)
• Medic-Alert identification recommended

1. Psychosocial support:

• Address secondary depression (PHQ-9: 12) — expected to improve with narcolepsy treatment and social re-engagement
• Connect with narcolepsy support organizations (Narcolepsy Network, Wake Up Narcolepsy)
• Educate roommate and close friends about the condition (especially cataplexy — it is not a seizure, not fainting, and not psychogenic)
• Consider narcolepsy peer mentorship program

1. Follow-up:

• Clinic visit at 2 weeks after starting medication to assess response and side effects
• Monthly visits for the first 3 months, then every 3-6 months
• Monitor weight (sodium oxybate can cause weight loss; stimulants can suppress appetite)
• Annual evaluation: review medication efficacy, side effects, cataplexy frequency log

Key Learning Points

• Narcolepsy type 1 is caused by autoimmune destruction of hypocretin (orexin)-producing neurons in the lateral hypothalamus, resulting in near-complete loss of CSF hypocretin-1; the HLA-DQB1*06:02 allele confers susceptibility, and environmental triggers (infections, H1N1 vaccination with Pandemrix adjuvant) may initiate the autoimmune process.
• The average delay from symptom onset to narcolepsy diagnosis is 8-15 years; symptoms are frequently misattributed to depression, laziness, epilepsy, or psychiatric disorders. Cataplexy, when present, is pathognomonic and should prompt immediate diagnostic workup.
• The MSLT must be performed after a preceding overnight PSG (to exclude other sleep disorders and verify adequate sleep) and after discontinuation of REM-suppressing medications (antidepressants, stimulants) for at least 2 weeks (5 half-lives for fluoxetine); failure to follow this protocol invalidates results.
• Sodium oxybate (gamma-hydroxybutyrate/GHB) is the only medication that addresses all four narcolepsy symptoms (sleepiness, cataplexy, hypnagogic hallucinations, and sleep paralysis) and is considered the most effective single agent, though it requires careful dose titration and has abuse potential.
• Abrupt withdrawal of REM-suppressing medications (SSRIs, SNRIs, TCAs) in patients with cataplexy can precipitate "status cataplecticus" — prolonged or continuous cataplexy that can be dangerous; these medications must always be tapered gradually.

All cases for this lecture as Markdown